|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT00473265 |
|
Date of registration:
|
14/05/2007 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Bone Properties in Hypoparathyroidism: Effects of PTH
|
|
Scientific title:
|
Bone Properties in Hypoparathyroidism: Effects of PTH |
|
Date of first enrolment:
|
May 2004 |
|
Target sample size:
|
68 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT00473265 |
|
Study type:
|
Interventional |
|
Study design:
|
|
|
Phase:
|
Phase 2/Phase 3
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
John P Bilezikian, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Columbia University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Hypoparathyroidism
Exclusion Criteria:
- Bisphosphonate use
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Hypoparathyroidism
|
|
Intervention(s)
|
|
Drug: PTH
|
|
Primary Outcome(s)
|
|
Requirements for Calcium Supplementation
[Time Frame: 2 years]
|
|
Secondary Outcome(s)
|
|
Percent Change in BMD From Baseline to 24 Months by DXA
[Time Frame: baseline versus 24 months]
|
|
Mineralizing Surface
[Time Frame: baseline versus one year]
|
|
Trabecular Number
[Time Frame: baseline versus two years]
|
|
Trabecular Width
[Time Frame: baseline versus two years]
|
|
Cortical Porosity
[Time Frame: baseline versus two years]
|
|
Secondary ID(s)
|
|
R01DK069350
|
|
AAAA5457
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|